CCRNCROSS COUNTRY HEALTHCARE INC(CCRN)Stock Analysis

AI analysis on 2,800+ stocks →
IndustrialsNasdaq
Institutional-grade research for retail investors
SEC EDGAR: CIK 1141103CCRN stock profile & AI dashboard →

13F Pro Quality Score

34.5/100

Rank #2,194 of 2,879 stocks

View Industrials peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

4.7/100

Profitability

31.1/100

Balance Sheet

26.3/100

Earnings Quality

30.0/100

Free Cash Flow

42.7/100

Institutional Flow

90.1/100

Revenue Scale

50.6/100

Dilution Risk

67.8/100

CCRN Stock Analysis & AI Quality Score

AI stock analysis and institutional research for CROSS COUNTRY HEALTHCARE INC (CCRN), a Industrials sector company. 13F Pro's AI-powered ranking engine scores CCRN at 34.5/100 on a 32-signal composite quality model, placing it at rank #2,194 of 2,879 stocks — the bottom half of the AI-ranked universe. CCRN scores in the top quartile across institutional flow (90.1). Areas of concern include revenue growth (4.7) and balance sheet strength (26.3), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q1 2026), CROSS COUNTRY HEALTHCARE INC reports quarterly revenue of $241.1M, net income of $-4.3M, free cash flow of $3.3M. Top institutional holders of CCRN by reported 13-F value include Boston Partners, BlackRock,, DIMENSIONAL FUND ADVISORS, based on the most recent SEC filings. CCRN trades on the Nasdaq exchange and files with the SEC under CIK 1141103. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CCRN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CROSS COUNTRY HEALTHCARE INC directly from SEC EDGAR. CROSS COUNTRY HEALTHCARE INC's 13F Pro composite quality score has ranged between 29 and 70 since 2021, currently 34.5 — a declining long-term trajectory across 28 quarterly and live scoring snapshots.

Revenue

Q1 2026

$241.1M

Net Income

Q1 2026

$-4.3M

Free Cash Flow

Q1 2026

$3.3M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-21.6% YoY
$1.05BFY 2025
FY22 $2.80BFY23 $2.02BFY24 $1.34BFY25 $1.05B

Net Income

-551.6% YoY
$-94.9MFY 2025
FY22 $186.0MFY23 $72.6MFY24 $-14.6MFY25 $-94.9M

Operating Income

-400.5% YoY
$-84.4MFY 2025
FY22 $269.9MFY23 $112.7MFY24 $-16.9MFY25 $-84.4M

EPS (Diluted)

-565.9% YoY
$-2.93FY 2025
FY22 $4.95FY23 $2.05FY24 $-0.44FY25 $-2.93

Total Assets

-23.8% YoY
$449.0MFY 2025
FY22 $949.6MFY23 $681.1MFY24 $589.3MFY25 $449.0M

Total Debt

FY 2025
FY22 $150.7MFY23 FY24 FY25

Op. Cash Flow

-59.8% YoY
$48.3MFY 2025
FY22 $134.1MFY23 $248.5MFY24 $120.1MFY25 $48.3M

AI Insight: CCRN Financial Trends

Revenue has declined 29% from Q2 2024 to Q1 2026, with Q4 2025 delivering a catastrophic $83M net loss that erased $96M of equity.

Revenue fell from $340M in Q2 2024 to $241M in Q1 2026, an eight-quarter uninterrupted contraction of nearly 29%.

Operating income has been negative in 7 of 8 quarters, worsening sharply to -$72M in Q4 2025 from -$6M in Q2 2025.

Equity eroded from $433M in Q2 2024 to $313M in Q1 2026, a $120M decline driven largely by the Q4 2025 net loss.

Operating cash flow turned positive at $18M in Q4 2025 and $5M in Q1 2026 despite deep net losses, offering a faint offset.

Q4 2025's $83M net loss — far exceeding any prior quarter — warrants scrutiny for impairment charges or one-time write-downs.

Equity has dropped to $313M in Q1 2026; continued losses risk further balance sheet deterioration with no debt data visible.

Revenue stabilized slightly to $241M in Q1 2026 from $237M in Q4 2025 — watch whether this marks a bottom or a pause.

AI Insight: CCRN Ratio Trends

A massive Q4 2025 write-down (-30.2% OpMargin, -102.8% ROE) masks a modest Q1 2026 stabilization, but CCRN has not posted a positive operating margin since Q3 2024.

Operating margin turned negative after Q3 2024's 0.9% peak, deteriorating to -30.2% in Q4 2025 before partially recovering to -1.7% in Q1 2026.

ROE collapsed to -102.8% in Q4 2025 from -0.5% in Q1 2025, reflecting a severe one-off charge that quarter.

Q1 2026 shows sequential improvement: OpMargin recovered to -1.7% and ROE to -5.5% from Q4 2025's extreme lows.

TTM OpMargin of -8.7% and ROE of -31.5% remain deeply negative — sustained profitability recovery is not yet visible in trailing figures.

Monitor whether Q4 2025's charge was truly one-off; recurrence would extend the unbroken streak of quarterly operating losses.

D/E data is absent across all periods — leverage position is unquantifiable, adding balance-sheet uncertainty.

Get alerted when CCRN's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for CROSS COUNTRY HEALTHCARE INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Put CCRN on your watchlist

Track score changes the day CROSS COUNTRY HEALTHCARE INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is CCRN a good stock to buy?

13F Pro's AI-powered analysis of CROSS COUNTRY HEALTHCARE INC (CCRN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Industrials sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CCRN are available on the CCRN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own CCRN?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CCRN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of CROSS COUNTRY HEALTHCARE INC's investment landscape.